Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CEP-37440 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CEP-37440 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CEP-37440 | DRUG | CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily. Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined. |
Inclusion Criteria: * Patients must have histologic or cytologic evidence of a solid neoplasm for which no standard therapy is available, or have progressed despite standard therapy, or are intolerant to standard therapy. * Patients must have evidence of recurrent, locally advanced, or metastatic d...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
CEP-37440 is an investigational small molecule being studied for the treatment of advanced or metastatic solid tumors. It was evaluated in a Phase 1 clinical trial in adult patients with solid tumors. It is not approved for any indication and remains in clinical development.
CEP-37440 targets ALK and PTK2 (also known as FAK). It is a small molecule inhibitor of both kinases. Targeting ALK and PTK2 is intended to interfere with signaling pathways involved in tumor growth and survival.
CEP-37440 is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva is the sponsor of the clinical program evaluating CEP-37440 in solid tumors.
CEP-37440 is in Phase 1 clinical development. It has completed one Phase 1 trial and has no active trials. The drug is investigational and has not been approved by the FDA for any indication.
CEP-37440 was studied in a single Phase 1 trial, NCT01922752, titled "To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors." The trial enrolled 32 patients in the United States and is completed.
Yes, the CEP-37440 Phase 1 trial NCT01922752 was biomarker-selected, meaning patient enrollment was guided by specific biomarkers. The trial evaluated oral CEP-37440 in adults with advanced or metastatic solid tumors and completed with 32 participants.